Imad Shureiqi

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. doi request reprint Curcumin chemoprevention: the long road to clinical translation
    Imad Shureiqi
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Cancer Prev Res (Phila) 4:296-8. 2011
  2. pmc The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis
    Imad Shureiqi
    Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Cancer Res 65:11486-92. 2005
  3. pmc The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer
    Imad Shureiqi
    Department of Clinical Cancer Prevention, Unit 1360, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    FASEB J 21:743-53. 2007
  4. pmc The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells
    Imad Shureiqi
    Departments of Clinical Cancer Prevention, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 100:9968-73. 2003
  5. pmc Clinical and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy
    I Shureiqi
    The University of Texas M D Anderson Cancer Center, Department of Clinical Cancer Prevention, 1515 Holcombe Boulevard, Box 236, Houston, TX 77030, USA
    Br J Cancer 86:226-32. 2002
  6. ncbi request reprint GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells
    Imad Shureiqi
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Res 62:1178-83. 2002
  7. pmc Effects of gut-targeted 15-LOX-1 transgene expression on colonic tumorigenesis in mice
    Xiangsheng Zuo
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Natl Cancer Inst 104:709-16. 2012
  8. pmc Global quantitative assessment of the colorectal polyp burden in familial adenomatous polyposis by using a web-based tool
    Patrick M Lynch
    Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Gastrointest Endosc 77:455-63. 2013
  9. pmc Mechanistic contribution of ubiquitous 15-lipoxygenase-1 expression loss in cancer cells to terminal cell differentiation evasion
    Micheline J Moussalli
    Department of Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Prev Res (Phila) 4:1961-72. 2011
  10. pmc Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer
    YuanQing Wu
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Mol Ther 16:886-92. 2008

Research Grants

Collaborators

Detail Information

Publications25

  1. doi request reprint Curcumin chemoprevention: the long road to clinical translation
    Imad Shureiqi
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Cancer Prev Res (Phila) 4:296-8. 2011
    ..This perspective discusses the potential significance and limitations of the current study findings in addressing the question of whether curcumin is clinically active as a chemopreventive agent...
  2. pmc The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis
    Imad Shureiqi
    Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Cancer Res 65:11486-92. 2005
    ..Therefore, 15-LOX-1 down-regulation rather than a shift in the balance of LOXs is likely the dominant alteration in LOX metabolism which contributes to colorectal tumorigenesis by repressing apoptosis...
  3. pmc The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer
    Imad Shureiqi
    Department of Clinical Cancer Prevention, Unit 1360, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    FASEB J 21:743-53. 2007
    ..Maintaining 15-LOX-1 transcriptional silencing in cancer cells is a multifactorial process involving GATA-6 overexpression and other regulatory events...
  4. pmc The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells
    Imad Shureiqi
    Departments of Clinical Cancer Prevention, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 100:9968-73. 2003
    ..Our findings indicate that the down-regulation of PPAR-delta by 15-LOX-1 through 13-S-HODE is an apoptotic signaling pathway that is activated by NSAIDs...
  5. pmc Clinical and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy
    I Shureiqi
    The University of Texas M D Anderson Cancer Center, Department of Clinical Cancer Prevention, 1515 Holcombe Boulevard, Box 236, Houston, TX 77030, USA
    Br J Cancer 86:226-32. 2002
    ..The use of multiple gated acquisition scans for pretreatment screening appears to be more cost-effective for patients who are 40 years or older, when cumulative doxorubicin dose is 350 mg m(-2) or less...
  6. ncbi request reprint GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells
    Imad Shureiqi
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Res 62:1178-83. 2002
    ..Ectopic GATA-6 expression blocked NSAID induction of 15-LOX-1 and apoptosis. NSAIDs down-regulate GATA-6 to transcriptionally up-regulate 15-LOX-1 and induce apoptosis in colorectal cancer cells...
  7. pmc Effects of gut-targeted 15-LOX-1 transgene expression on colonic tumorigenesis in mice
    Xiangsheng Zuo
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Natl Cancer Inst 104:709-16. 2012
    ....
  8. pmc Global quantitative assessment of the colorectal polyp burden in familial adenomatous polyposis by using a web-based tool
    Patrick M Lynch
    Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Gastrointest Endosc 77:455-63. 2013
    ..Accurate measures of the total polyp burden in familial adenomatous polyposis (FAP) are lacking. Current assessment tools include polyp quantitation in limited-field photographs and qualitative total colorectal polyp burden by video...
  9. pmc Mechanistic contribution of ubiquitous 15-lipoxygenase-1 expression loss in cancer cells to terminal cell differentiation evasion
    Micheline J Moussalli
    Department of Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Prev Res (Phila) 4:1961-72. 2011
    ..Our findings indicate that 15-LOX-1 downregulation in cancer cells is an important mechanism for terminal cell differentiation dysregulation and support the potential therapeutic utility of 15-LOX-1 reexpression to inhibit tumorigenesis...
  10. pmc Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer
    YuanQing Wu
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Mol Ther 16:886-92. 2008
    ..These data provide the rationale for further development of therapeutic strategies to target 15-LOX-1 molecularly for treating colonic tumorigenesis...
  11. pmc 15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation
    Xiangsheng Zuo
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    FASEB J 22:1981-92. 2008
    ..DNMT-1 has a direct suppressive role in 15-LOX-1 transcriptional silencing that is independent of 15-LOX-1 promoter DNA methylation...
  12. pmc 15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in?
    Sun Il Lee
    Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Metastasis Rev 30:481-91. 2011
    ..Re-expression of 15-LOX-1 in colon cancer cells can function as an important therapeutic mechanism and could be further exploited to develop novel treatment approaches for this common cancer...
  13. pmc Targeted genetic disruption of peroxisome proliferator-activated receptor-delta and colonic tumorigenesis
    Xiangsheng Zuo
    Department of Clinical Cancer Prevention, Unit 1360, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Natl Cancer Inst 101:762-7. 2009
    ..Increased expression of vascular endothelial growth factor in colon tumors vs normal colon was suppressed by loss of PPAR-delta expression. These findings indicate that PPAR-delta has a crucial role in promoting colonic tumorigenesis...
  14. pmc Chromatin modification requirements for 15-lipoxygenase-1 transcriptional reactivation in colon cancer cells
    Xiangsheng Zuo
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Biol Chem 283:31341-7. 2008
    ..These findings demonstrate that histone modification in the 15-LOX-1 promoter is important to 15-LOX-1 transcriptional silencing in colon cancer cells and that HDACIs can activate gene transcription via KDM3A demethylation of H3K9me2...
  15. ncbi request reprint Determination of endogenous tissue inflammation profiles by LC/MS/MS: COX- and LOX-derived bioactive lipids
    Peiying Yang
    Departments of Experimental Therapeutics, The University of Texas, M D Anderson Cancer Center, 8000 El Rio, Houston, TX 77054, USA
    Prostaglandins Leukot Essent Fatty Acids 75:385-95. 2006
    ....
  16. pmc Profiling lipoxygenase metabolism in specific steps of colorectal tumorigenesis
    Imad Shureiqi
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, 77030 4009, USA
    Cancer Prev Res (Phila) 3:829-38. 2010
    ..15-LOX-1 inhibited interleukin-1beta expression. This study establishes that reduced 13-HODE levels are a specific alteration in the LOX product profile associated with human colorectal tumorigenesis...
  17. pmc Eicosanoid profiling in colon cancer: emergence of a pattern
    Xiangsheng Zuo
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Prostaglandins Other Lipid Mediat 104:139-43. 2013
    ..This shift occurs during the polyp formation stage and thus offers the opportunity to modulate tumorigenesis early by correcting 15-LOX-1 downregulation. ..
  18. doi request reprint Arachidonic acid metabolism in human prostate cancer
    Peiying Yang
    Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Int J Oncol 41:1495-503. 2012
    ..0.010 ng/mg protein, respectively; p=0.019). Our results suggest that LOX metabolites such as 12-HETE are critical in prostate cancer progression and that the LOX pathway may be a target for treating and preventing prostate cancer...
  19. ncbi request reprint The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells
    Linda C Hsi
    Department of Clinical Cancer Prevention, Gastrointestinal Medical Oncology, and Division of Cancer Prevention, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 64:8778-81. 2004
    ....
  20. pmc Targeting peroxisome proliferator-activated receptor-β/δ in colon cancer: how to aim?
    Min Xu
    Department of Gastrointestinal Medical Oncology, Unit 0426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Biochem Pharmacol 85:607-11. 2013
    ..Definitive studies are therefore needed to establish the exact role of PPARδ in human colorectal tumorigenesis and to provide a theoretical basis for PPARδ therapeutic targeting...
  21. doi request reprint Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway
    Scott Kopetz
    Department of Gastrointestinal Medical Oncology, M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 426, Houston, TX 77030, USA
    J Clin Oncol 26:2000-5. 2008
    ..It is unclear to what extent aspects of this "Critical Path Initiative" have been adopted in trial designs in metastatic colorectal cancer...
  22. doi request reprint Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial
    Prajnan Das
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas Electronic address
    Int J Radiat Oncol Biol Phys 88:301-5. 2014
    ..The goal of this phase 1 trial was to determine the maximum tolerated dose (MTD) of concurrent capecitabine, bevacizumab, and erlotinib with preoperative radiation therapy for rectal cancer...
  23. ncbi request reprint Lipoxygenase modulation to reverse carcinogenesis
    I Shureiqi
    Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 61:6307-12. 2001
    ..e., agents that can induce the anticarcinogenic and/or inhibit the procarcinogenic LOXs, thereby shifting the balance of LOX activities from procarcinogenic to anticarcinogenic metabolism of polyunsaturated fatty acids...
  24. ncbi request reprint Activation of protein kinase G up-regulates expression of 15-lipoxygenase-1 in human colon cancer cells
    Atsuko Deguchi
    Department of Medicine and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA
    Cancer Res 65:8442-7. 2005
    ..Taken together, these results provide evidence that the cGMP/PKG pathway can play an important role in the induction of 15-LOX-1 expression by nonsteroidal antiinflammatory drugs and related agents...
  25. ncbi request reprint Can selenium prevent colorectal cancer? A signpost from epidemiology
    Anna J Duffield-Lillico
    J Natl Cancer Inst 96:1645-7. 2004

Research Grants12

  1. 15-LOX-1 effects on colitis and colon cancer
    Imad Shureiqi; Fiscal Year: 2010
    ..This improved understanding is expected to facilitate the identification of molecular targets for new strategies for colon cancer prevention. ..
  2. 15-LOX-1 effects on colitis and colon cancer
    Imad Shureiqi; Fiscal Year: 2009
    ..This improved understanding is expected to facilitate the identification of molecular targets for new strategies for colon cancer prevention. ..
  3. Molecular Targeting of 15-Lipoxygenase-1 in Colon Cancer
    Imad Shureiqi; Fiscal Year: 2007
    ..the feasibility of tumor selective targeting of 15-LOX-1 to inhibit tumorigenesis will pave the way for future preclinical and clinical development of therapeutic strategies based on molecularly targeting 15-LOX-1 ..
  4. 5-LOX-1 and Clinical Chemoprevention of Colon Tumors
    Imad Shureiqi; Fiscal Year: 2007
    ..If our hypothesis is confirmed, efforts can be directed to develop chemopreventive interventions that specifically target the GATA-6 and 15-LOX-1 signaling pathway. ..
  5. LINOLEIC ACID METABOLISM AND COLON CARCINOGENESIS
    Imad Shureiqi; Fiscal Year: 2005
    ..This work will set the stage for future animals and clinical studies of LA alternative pathway modulation as means of colon cancer chemoprevention. ..
  6. Molecular targeting of PPAR-delta in colon cancer
    Imad Shureiqi; Fiscal Year: 2010
    ..This improved understanding is expected to help determine whether PPAR-d would be a suitable molecular target for development of new drugs to treat colon cancer. ..